Your browser doesn't support javascript.
loading
Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism.
Glaenzel, Ulrike; Jin, Yi; Nufer, Robert; Li, Wenkui; Schroer, Kirsten; Adam-Stitah, Sylvie; Peter van Marle, Sjoerd; Legangneux, Eric; Borell, Hubert; James, Alexander D; Meissner, Axel; Camenisch, Gian; Gardin, Anne.
Afiliação
  • Glaenzel U; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.) ulrike.glaenzel@novartis.com.
  • Jin Y; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
  • Nufer R; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
  • Li W; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
  • Schroer K; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
  • Adam-Stitah S; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
  • Peter van Marle S; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
  • Legangneux E; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
  • Borell H; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
  • James AD; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
  • Meissner A; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
  • Camenisch G; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
  • Gardin A; PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).
Drug Metab Dispos ; 46(7): 1001-1013, 2018 07.
Article em En | MEDLINE | ID: mdl-29735753

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azetidinas / Compostos de Benzil / Receptores de Lisoesfingolipídeo / Citocromo P-450 CYP3A / Citocromo P-450 CYP2C9 Tipo de estudo: Diagnostic_studies Limite: Adolescent / Adult / Animals / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azetidinas / Compostos de Benzil / Receptores de Lisoesfingolipídeo / Citocromo P-450 CYP3A / Citocromo P-450 CYP2C9 Tipo de estudo: Diagnostic_studies Limite: Adolescent / Adult / Animals / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article